Statements (78)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
tyrosine kinase inhibitor
|
| gptkbp:appointed_by |
oral tablet
once daily |
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:brand |
gptkb:Lenvima
|
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
Phase 3
NC T01321582 NC T01776313 NC T01902445 NC T02041260 NC T02210117 NC T01321554 NC T01710124 NC T02210157 |
| gptkbp:contraindication |
severe renal impairment
severe hepatic impairment hypersensitivity to lenvatinib |
| gptkbp:developed_by |
gptkb:Daiichi_Sankyo
|
| gptkbp:developer |
gptkb:Eisai
|
| gptkbp:effective_date |
gptkb:2015
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lenvatinib
|
| gptkbp:indication |
gptkb:differentiated_thyroid_cancer
advanced hepatocellular carcinoma advanced renal cell carcinoma unresectable thyroid cancer unresectable hepatocellular carcinoma |
| gptkbp:ingredients |
C22 H22 N4 O4 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:invention |
U S20130204212 A1
U S20140007412 A1 U S20150007412 A1 U S20160007412 A1 U S20170007412 A1 |
| gptkbp:is_atype_of |
L01 X E30
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
gptkb:hepatocellular_carcinoma treatment of thyroid cancer treatment of kidney cancer treatment of liver cancer |
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe gptkb:Lenvima |
| gptkbp:pharmacokinetics |
metabolized by liver
bioavailability 24% half-life 28 hours |
| gptkbp:safety_features |
risk of liver toxicity
risk of gastrointestinal perforation risk of heart failure risk of bleeding risk of thromboembolic events |
| gptkbp:side_effect |
fatigue
nausea hypertension weight loss decreased appetite diarrhea stomatitis hand-foot syndrome |
| gptkbp:targets |
gptkb:FGFR
gptkb:VEGFR gptkb:PDGFR KIT RET |
| gptkbp:type_of |
417716-92-4
|
| gptkbp:weight |
414.50 g/mol
|
| gptkbp:bfsParent |
gptkb:Eisai
|
| gptkbp:bfsLayer |
4
|